Introduction
Non-ischaemic dilated cardiomyopathy (DCM) is one of the leading causes of heart failure worldwide and represents a significant cause of morbidity and mortality. 1, 2 Besides cardiomyocyte cell loss, extracellular matrix remodelling and interstitial fibrosis, a significant proportion of cases have an underlying inflammatory background. [3] [4] [5] [6] [7] [8] Endomyocardial biopsy (EMB) still represents the 'gold standard' for detecting myocardial inflammation and interstitial fibrosis, 9 but its invasiveness and inherent sampling error limit its widespread use in clinical practice. However, biopsy findings carry clear treatment implications in DCM patients if giant cell myocarditis or sarcoidosis can be diagnosed. 10 Beyond this, molecular genetic analysis for cardiotropic viruses can delineate whether chronic inflammation is caused by viral persistence or autoimmunity to cardiac proteins. This may help to tailor immunosuppressive treatment in selected patients. 11 Moreover, a European Society of Cardiology (ESC) Working Group recently called for broader use of EMB to improve detection of myocardial inflammation. 9 Thus, there is emerging medical need to identify those patients who could benefit from EMB. Cardiovascular magnetic resonance (CMR) imaging allows noninvasive assessment of cardiac function and anatomy with high spatial and temporal resolution. Parametric CMR approaches, quantifying native T1 and T2 relaxation times, have increased diagnostic accuracy for detection of myocardial inflammation, for example in acute myocarditis. [12] [13] [14] [15] This was also true for myocarditis with chronic symptoms. 16 Recently, elevated T2 values have been reported in patients with idiopathic DCM. 17 However, no study validated T2 values against the diagnostic gold standard EMB in these patients. Therefore, the aim of this study was to determine the diagnostic accuracy of T2 mapping to detect biopsy-proven myocardial inflammation in DCM using approaches, which have recently been validated in patients with myocarditis.
Methods

Study population
The ethical board of the Heinrich-Heine University Düsseldorf, Germany, approved this study (application number 4307). The study complies with the declaration of Helsinki. A total of 132 subjects were enrolled between 2013 and 2016: 62 controls and 70 patients with DCM. Data analysis was performed retrospectively after data collection. Diagnosis of DCM was made according to the current ESC guidelines 2 in patients with left ventricular dilatation and systolic dysfunction in the presence of normal wall thickness and in the absence of abnormal loading conditions and coronary artery disease. Left ventricular dilatation was defined by left ventricular end-diastolic volume >2 SD from controls, according to normograms and corrected by body surface area, age, and gender. 18 All patients underwent CMR, coronary angiography, and EMB.
The time between EMB and CMR examination was 3 ± 2 days. We divided the patients into two groups depending on the severity of left ventricular systolic dysfunction. Mean left ventricular ejection fraction (LVEF) of patients with DCM was 30 ± 11%. Patients with LVEF above 30% were considered as having mild DCM, whereas patients with LVEF below 30% were summarized as severe DCM.
Exclusion criteria of the study were (i) poor CMR image quality (ii) coronary artery disease (coronary stenosis >50% proven by angiography) (iii) pre-existing other cardiac disease that could explain symptoms, and (iv) contraindications against CMR.
Sixty age, gender, and cardiovascular risk factor-matched volunteers served as controls. A schematic study protocol is given in Figure 1 .
CMR imaging and analysis
CMR was performed using a 1.5 T scanner (Achieva, Philips, Best, Netherlands) with a 32-channel phased array coil. CINE loops in shortaxis slices were assessed to calculate left ventricular function.
For oedema imaging, a T2-weighted TSE-STIR sequence was used and T2 mapping was conducted with a GRASE sequence in three short-axis slices (basal, midventricular, and apical). This sequence combines the TSE and echo-planar imaging methods using a train of refocusing 180 pulses and an odd number of additional gradient echoes for each spin echo. Cardiac triggering and respiration navigator gating was done with the following parameters: TR = 1 RR interval, number of echo images = 15, echo spacing 10 ms, leading to an echo train of 150 ms, number of gradient echoes for segmented acquisition = 3 (EPI factor), FA = 90 , spatial resolution: 2Â 2Â10 mm 3 , parallel imaging (SENSE) with an accelerating factor of 2, k-space data acquired with Cartesian encoding scheme. For blood saturation, a double inversion (black-blood) pulse was applied. 19 Late gadolinium enhancement (LGE) imaging was carried out 8-10 min after gadolinium contrast injection (ProHance V R , Bracco Imaging) with a 3D-gradient spoiled turbo fast-field echo sequence with a nonselective 180 inversion-recovery pre-pulse triggered to end diastole acquired in the short axis, four, three, and two-chamber view to cover the whole ventricle.
Post-processing
For post-processing, left ventricular function and LGE were analysed offline using commercial software (Extended Workspace, Philips Healthcare).
LGE was assessed by visual assessment and assignment of certain myocardial parts according to the 17-segment model of the American Heart Association (AHA).
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T2 maps were generated according to Bönner et al. 19 T2 maps were generated offline using software based on the graphical programming language LabVIEW (National Instruments, Austin, TX, USA). An exponential decay curve was fitted to the intensity decline of each pixel within the images obtained from the multi-echo sequence. We applied a twoparameter (amplitude and damping) fit model with a constant offset. The bias was calculated from the noise of all echo images and supposed to be constant, so that the problem could be linearized and the regression coefficient (R 2 ) could be applied as a goodness-of-fit parameter to exclude accidental values. If R 2 was not within a tolerance interval chosen to be 0.7 and 1, the corresponding T2 value was not regarded for further calculations. The resulting T2 constants were colour coded using the spectral lookup table. Endo-and epimyocardial region of interests (ROIs) were drawn manually in the first echo image of the echo train. Myocardial ROIs were assessed according to the AHA 17-segment model, 20 and T2 values were calculated for 16 segments (segment 17 was not considered). To avoid spill over of high T2 values due to epicardial fat and endocardial slow flow artefacts, a T2 time limit of 110 ms was defined in the final absolute T2 time.
Histological analysis
Five to eight biopsy samples were taken from the septal and apical regions from the right ventricle during X-ray-guided EMB. Histological, immunohistological, and molecular pathological analyses were performed according to consensus recommendations. 9 Multiple sections of 5 lm thickness were stained with haematoxylin-eosin and Masson's trichrome and examined using light microscopy. Immunohistochemistry for characterization of inflammatory infiltrates was performed by the use of the following antibodies: CD3 and CD68. The presence of >14 infiltrating leucocytes/mm 2 and the presence of >2 CD3-positive lymphocytes per high-power field were considered as diagnostic for myocardial inflammation. 9 The degree of fibrosis was assessed by experienced pathologists and graduated to the following three categories by subjective grading: no fibrosis, mild fibrosis, and severe fibrosis. Experienced operators performed analyses of CMR imaging and EMB in a blinded fashion. 
Statistical analysis
Statistical analysis was performed with GraphPad Prism 7 (Graphpad Software, San Diego, CA, USA). Unless otherwise stated, normally distributed data are presented as mean value ± standard deviation.
Proportions are expressed as the number of patients and percentages. Data were statistically analysed by the paired or unpaired Student's t-test.
Fisher's exact test was used to examine the significance of the association between two kinds of classification. A receiver operating curve (ROC) analysis was performed to calculate optimal thresholds and areas under the curves (AUCs). P-values below 0.05 were assumed to be significant.
Results
Baseline patient characteristics Figure 1 displays the study flow chart. A total of 70 patients matched the defined criteria for diagnosis of DCM and received EMB. Thirteen patients had to be excluded due to poor CMR image quality. Stratified by LVEF, 23 patients presented with mild DCM (LVEF > 30%) and 34 patients showed a severely reduced LVEF below 30%. Mean age within the total population was 46 ± 15 years ( Table 1) . The majority complained about fatigue (mild vs. severe DCM, 61 vs. 68%). Relevant dyspnoea according to the New York Heart Association (NYHA) functional Class III and IV was more prevalent in patients with severe DCM (68%) than in patients with mild DCM (48%).
Patients presenting with severely reduced LVEF had higher concentration of elevated NT-pro-BNP levels than patients with mild impairment. On the other hand, patients with mild stages of disease revealed higher troponin concentrations ( Table 1) . Cardiovascular risk factor profile was similar between both groups.
EMB results
Right ventricular EMB was performed in all patients. Myocardial inflammation was present in 25% of patients ( Table 2) . Interestingly, the presence of inflammation was equally distributed between patients with mild and severe DCM (26 vs. 24%). Viral genomes were detected in 39% (22/57) of all patients, again with equal distribution between the groups, with parvovirus B19 being the most common virus genome. There was no correlation between the presence of viral genome and the myocardial inflammation. EMB analysis revealed that most patients had mild-to-moderate interstitial fibrosis (35/57), whereas 25% (14/57) showed no signs of fibrosis and 14% (8/57) of patients showed the presence of severe fibrosis.
CMR imaging
Mean LVEF in patients with DCM (n = 57) was 30 ± 11%. Left ventricular dilatation was markedly increased in patients with severe DCM (LVEDV/BSA 150 ± 33 mL/m Table 3) .
LGE was present in 53% of all patients without any difference between both Figure 1 Study profile. One hundred and thirty-two subjects were enrolled to this study. Seventy patients with clinical diagnosis of DCM and 62 healthy controls met study inclusion criteria. Two controls as well as 13 patients had to be excluded because of invalid T2 maps due to artefacts. Analysis of 60 controls and 57 DCM patients who also underwent EMB was possible. DCM patients were divided into two groups according to the left ventricular systolic function.
groups. In this regard, 15 (26%) patients exhibited a typical midwall sign. Eleven (19%) patients revealed a patchy pattern of LGE, whereas the remaining patients showed focal (n = 3) or epicardial (n = 1) patterns of LGE. There was no significant correlation between the presence of fibrosis in biopsy specimens and the presence of highsignal intensity areas in LGE images.
Oedema ratio was increased (>1.9) in one-third of total patient population.
LGE as well as T2-weighted imaging was equally distributed in both groups. Moreover, there was no correlation between LGE, T2 weighted imaging, and the presence of inflammation in EMB.
T2 mapping
Global T2 time was significantly increased in patients with diagnosis of DCM compared with the healthy controls (T2 time DCM vs. controls: 65.9 ± 6.2 vs. 60.0 ± 4.2 ms; P < 0.001) (Figure 2) . There was no difference between patients with mild DCM and patients with severe DCM. However, as 
Prediction model based on ROC analysis
ROC analysis of our data identified a global myocardial T2 time > 65.3 ms as the best cut-off for distinction between the healthy controls and DCM patients with myocardial inflammation (sensitivity 93%, specificity 90%, P < 0.01, AUC 0.95, Figure 5 ). Adapted to all patients, this threshold identified 34 of 57 patients as having myocardial inflammation. However, compared with EMB as diagnostic gold standard, ROC analysis revealed a sensitivity of 79% and specificity of 58% (AUC 0.72) in discrimination of myocardial inflammation within all DCM patients.
Discussion
In this retrospective study, we investigated myocardial T2 relaxation times in patients with different stages of DCM in comparison with a cohort of age-, gender-, and risk factor-matched controls and further validated our findings against the EMB results. We demonstrated that (i) myocardial T2 time was increased in patients with DCM compared with the healthy controls; (ii) in biopsy-proven myocardial inflammation, T2 values are further elevated compared with non-inflamed myocardium; and (iii) a reliable differentiation remains challenging due to the wide overlap of T2 times between DCM with and without the presence of inflammatory cells. The results of our study have to be interpreted against the background of its retrospective nature and our study population according to the recent ESC guidelines. In this regard, it is quite challenging to clinically discriminate patients with acute myocarditis and mild cavity dilatation from patients with DCM and true ventricular dilatation due to overlapping disease characteristics and phenotypes. To account for this, we only included patients with prominent left ventricular end-diastolic volume >2 SD from normal controls, which were in line with normograms and corrected by body surface area, age, and gender. 18 T2 mapping has emerged as a valuable tool in the CMR assessment of myocardial edema in ischaemic and non-ischaemic cardiomyopathies. [21] [22] [23] Particularly in the CMR-based assessment of patients with acute myocarditis, T2 mapping demonstrated its ability to detect myocardial inflammation as has been validated by EMB. 15, 24 In this regard, it has already been shown that increased signal intensity ratios in T2-weighted images of DCM patients possibly reflected myocardial oedema. 25, 26 Here, we detected an increased signal intensity ratio in T2-weighted images in a subset of patients (13/57). However, there was no relation of semi-quantitative T2 thresholds to the presence or the absence of inflammatory cells, and diagnostic accuracy was similar to previous reports. 12, 27 This might, on the one hand, be due to the susceptibility of T2-weighted images for motion artefacts and, on the other hand, due to lacking histological methods for precise oedema quantification. However, there are several limitations, which hamper diagnostic accuracy of T2-weighted imaging, including susceptibility to myocardial motion, surface coil intensity variation, high subendocardial signal from static blood, and the subjective nature of image interpretation. [28] [29] [30] As we could demonstrate now, T2 mapping overcomes some of these limitations with subsequent better diagnostic accuracy. Recently, elevated T2 relaxations times have been published in patients with DCM. 17 To the best of our knowledge, there is no study validating T2 values in DCM against the EMB results. Here, we demonstrated increased T2 values in the majority of DCM patients compared with the controls and that T2 values further increased in the presence of inflammatory cells as determined by EMB. This was independent of the presence of viral genomes and the extent of interstitial fibrosis. The ability of T2 mapping to identify myocardial inflammation has already been shown by our group and others. 15, 16, 24 Previously, we reported a global T2 time of 68.2 ± 6.4 ms in patients with biopsyproven myocarditis. 15 Now, we detected a mean T2 time of 68.8 ± 5.6 ms in patients with DCM and the presence of inflammatory cells in EMB, which is very close to the previous reported values.
ROC analysis indicated a global myocardial T2 time > 65.3 ms as the best cut-off for distinction between healthy and inflamed myocardium (sensitivity 93%, specificity 90%, P < 0.01, AUC 0.95). Adapted to all patients with DCM, this threshold identified 34 of 57 patients as having myocardial inflammation, even in many patients with negative EMB results. This phenomenon has already been described in patients with recent onset heart failure 24 as well as in patients with acute and chronic myocarditis. 16 The reason for this phenomenon
remains questionable yet. Theoretically, there can be myocardial oedema without relevant presence of inflammatory cells, because the diagnosis of inflammation in EMB is based on leucocyte numbers. Microvascular dysfunction with transient episodes of ischaemia might additionally affect myocardial T2 values. 31 Moreover, taking the theoretical sampling error of EMB into account, the immune histological analysis is restricted to the area of EMB. Therefore, adjacent or remote leucocyte infiltration might have been missed. However, the differentiation between DCM patients with and without myocardial inflammation on the basis of T2 mapping remains challenging. The defined cut-off (T2 time > 65.3 ms) revealed a sensitivity of 79% and a specificity of 58% (AUC 0.72) in discrimination of myocardial inflammation within all DCM patients. Although this is in line with previous reports in myocarditis, 12, 16, 24 diagnostic accuracy is low for any clinical application and illustrates one of the main limitations of the technique. Even though the average value between groups may differ significantly, it is hard to categorize individuals on the basis of T2 values due to a wide overlap of values. Figure 2 reflects this limitation of T2 mapping in general, as there is a wide overlap of average T2 times in controls and patients with DCM.
Since T2 values tend to vary in the same individual depending on slice location, sequence design, vendor and post-processing tools, and even more between individuals depending on age, gender, and co-morbidities, T2 reference values were determined in a matched group of healthy controls using standardized protocols. 19 
Clinical implications of T2 mapping in DCM
Chronic myocardial injury caused by post-infectious immune or autoimmune processes is responsible for progressive ventricular dilatation and dysfunction. 32, 33 Sometimes myocarditis presents as an acute form of DCM, thus discrimination of both entities is challenging. However, one important and treatable feature in acute myocarditis, chronic myocarditis, and DCM is the presence of myocardial inflammation. [34] [35] [36] There are convincing data on the prognostic role of EMB and detailed analysis of inflammation as well as the presence of viral genome. In 181 patients, evidence of inflammatory infiltrates was demonstrated to predict cardiovascular death and heart transplantation. 37 Besides prognostic implications, several biopsy findings carry clear therapy implications (e.g. giant cell myocarditis and sarcoidosis). Detection and elimination of viral genomes from myocardium seems to play a key role for the treatment of virus-positive inflammatory cardiomyopathy. Regarding virus-negative inflammatory cardiomyopathy, immunosuppression demonstrated improvements in left ventricular function. 11 Thus, myocardial inflammation with or without the presence of viral genome is an exciting prospect for mechanism-based therapy in DCM. These thoughts require a broader use of EMB, which emphasizes the role of patient selection on the basis of the presence of inflammation. CMR enables a non-invasive assessment of myocardial inflammation, which may be important to improve patient selection for EMB. The present T2 mapping approach detects inflammation in DCM patients as has been proved by EMB and therefore enables an additional stratification of DCM based on T2 values. Further studies including alternative biopsy-based approaches for sophisticated EMB analysis are warranted to reveal the nature of T2 time elevation, despite immune-histological negative EMB. 38 At the horizon, noninvasive T2 mapping might aid in the selection process of patients undergoing EMB and therefore influence therapy strategies in patients suffering from persistent myocardial inflammation who may benefit from tailored immunosuppressive therapy.
Limitations
We defined DCM only on morphologic rather than aetiologic criteria. However, this would have been interesting with respect to a better pathophysiological understanding. EMB was conducted only in the right ventricular side of the interventricular septum, which is a major limitation of this study, as the diagnostic accuracy of one ventricular alone is inferior compared with the biventricular biopsy. 39, 40 Furthermore, it has recently been shown that 18% of myocarditis cases are missed by selective right ventricular biopsy sampling. 41 Therefore, biventricular biopsy sampling might have strengthened our findings.
In addition, we want to accentuate that the image quality of 13 of 70 (19%) patients was insufficient for analysis due to artefacts (mainly blurring). These artefacts were predominately located in the inferior and lateral segments in midventricular and apical layers. Since these segments are frequently affected in myocarditis, we chose to exclude these patients and not only affected segments from our analysis. We suggest that most of these artefacts arise from partial volume and motion effects. However, despite this finding is in line with previous reports, 42, 43 we only accepted images without visual artefacts, being aware of a potential selection bias. Furthermore, the threshold of 65.2 ms global T2 time as determined by ROC analysis needs to be validated in a prospective cohort before being promoted as valid in this regard. Again, we would like to emphasize that T2 reference values need to be established individually for each scanner and sequence as individual values are dependent on a variety of factors, including field strength, vendor, sequence design, and post-processing.
Conclusions
In patients with DCM and the presence of inflammatory cells in the myocardium, quantification of myocardial T2 relaxation times may help to non-invasively detect myocardial inflammation. Although there is an overlap of T2 values between patients and healthy controls, T2 mapping may facilitate the identification of patients who may benefit from EMB for therapeutic decision-making.
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